Video Series

Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, while acknowledging both the opportunities and challenges that lie ahead in clinical practice.

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care and incorporating recent advances like new therapeutic options and refined diagnostic criteria.

Toby Maher, MD, PhD, discusses how delays in treatment for idiopathic pulmonary fibrosis (IPF) can significantly worsen patient outcomes and accelerate disease progression, underscoring the critical need for timely intervention.

Toby Maher, MD, PhD, discusses the various barriers that frequently hinder patients with idiopathic pulmonary fibrosis (IPF) from receiving appropriate treatment and shares effective strategies he has implemented to overcome these challenges.

Panelists conclude by highlighting key takeaways in the management of NSCLC.

Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.

Panelists discuss how health care providers and payers can collaborate more effectively to optimize lupus nephritis care.

Toby Maher, MD, PhD, discusses how common signs and symptoms of idiopathic pulmonary fibrosis (IPF) at diagnosis can indicate disease progression, while also identifying key risk factors associated with IPF and emphasizing the importance of modifying certain lifestyle factors to help prevent the disease.

Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is diagnosed through specific imaging and tests, with an average diagnosis time that can delay effective treatment, emphasizing that early diagnosis is crucial for reducing disease severity and expanding available treatment options.

Panelists discuss how unmet needs in type 2 inflammatory diseases require further research, including developing more personalized treatment approaches, identifying novel biomarkers for better disease phenotyping, improving long-term disease control strategies, and addressing the psychosocial impacts of chronic inflammatory conditions to enhance patients’ overall quality of life and outcomes.

The panel of experts concludes by exploring the implementation of cardiometabolic risk management learnings and the utilization of telehealth in clinical practice.

Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.

Experts examine strategies for coordinating initiatives to enhance cardiometabolic risk management care, focusing on incentivizing providers to deliver high-quality care to patients with cardiometabolic conditions.

A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.

Panelists discuss how integrating HER2-directed therapies into existing NSCLC decision-making processes presents challenges, focusing on strategies for timely updates as new therapies emerge and the practicalities of HER2- mutation testing, including turnaround times and result interpretation for therapy selection.

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support timely access, including how payers are facilitating care.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) severely affects patients’ quality of life and daily functioning, with a median survival that underscores the disease’s severity, while also highlighting the substantial financial burden and health care resource utilization associated with managing this condition.

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant respiratory impairment and distinct clinical challenges compared with other interstitial lung diseases.

Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.

Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.

A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.

Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.

A panel of cardiometabolic risk management experts analyzes key takeaways from the UH CINEMA Program.

Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ between nephrologists and rheumatologists.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.

Panelists discuss how type 2 inflammatory diseases can lead to potential long-term complications or comorbidities, including airway remodeling in asthma, nasal polyps in chronic rhinosinusitis, skin thickening in atopic dermatitis, and increased risk of cardiovascular issues and metabolic disorders.